Amiodarone-induced thyroid dysfunction (AITD) is a clinically significant complication, particularly in environmentally high-risk regions such as the Aral Sea area, where iodine deficiency and environmental pollution prevail. This study aimed to develop and validate an algorithm for early diagnosis and optimized management of AITD. A total of 98 patients receiving amiodarone therapy for cardiac arrhythmias were prospectively observed from 2022 to 2024. Thyroid dysfunction was classified as overt or subclinical hypothyroidism, overt or subclinical thyrotoxicosis, or euthyroid hyperthyroxinemia. Hormonal (TSH, free T4, free T3, TRAb, anti-TPO, anti-TG), biochemical, electrocardiographic, Holter, and echocardiographic parameters were assessed. Individualized therapy for hypothyroidism (L-thyroxine) and thyrotoxicosis (antithyroid drugs or glucocorticoids) was applied. The proposed algorithm enables early detection of AITD, optimization of therapy, prevention of complications, and improvement of patient outcomes in iodine-deficient regions.
| Published in | International Journal of Immunology (Volume 13, Issue 4) |
| DOI | 10.11648/j.iji.20251304.13 |
| Page(s) | 96-100 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2025. Published by Science Publishing Group |
Amiodarone-induced Thyroid Dysfunction, Thyrotoxicosis, Hypothyroidism, Early Diagnosis, Aral Sea Region, Arrhythmias, Patient Management
| [1] | Abdikadirova TS, Aliyeva AV, Trigulova RK, Nasirova HK. Amiodarone-induced thyrotoxicosis in patients living in iodine-deficient regions: cardiological consequences and clinical features. Zhurnal Teoreticheskoy i Klinicheskoy Meditsiny. 2025; 3: 49-53. |
| [2] | Bartalena L, Bogazzi F, Chiovato L, Hubalewska-Dydejczyk A, Links TP, Vanderpump M. 2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction. Eur Thyroid J. 2018; 7(2): 55-66. |
| [3] | Centanni M, Benvenga S, Sachmechi I. Diagnosis and management of treatment-refractory hypothyroidism: an expert consensus report. J Endocrinol Invest. 2017; 40(12): 1289-1302. |
| [4] | Epstein AE, Olshansky B, Naccarelli GV, Kennedy JI, Murphy EJ, Goldschlager N. Practical management guide for clinicians who treat patients with amiodarone. Am J Med. 2015; 129(5): 468-474. |
| [5] | Ermolaeva AS, Fadeev VV. Type 2 amiodarone-induced thyrotoxicosis: prevalence, time and predictors of development. Problemy Endokrinologii. 2023; 70(3): 9-15. |
| [6] | Ermolaeva AS, Fadeev VV. Type 2 amiodarone-induced thyrotoxicosis: efficacy of glucocorticoid therapy, a retrospective analysis. Problemy Endokrinologii. 2024; 69(6): 17-23. |
| [7] | Gaballa S, Naser N, Paál E, Sabyasachi S. PSAT335 Histopathological changes of the thyroid may be subtle yet important in amiodarone induced thyrotoxicosis (AIT). J Endocr Soc. 2022; 6(5): bvac150.1715. |
| [8] | Gasparini D, Raljevic D, Pejcinovic VP, et al. Amiodarone-induced thyroiditis and cardiomyopathy. Front Cardiovasc Med. 2023; 10: 1212965. |
| [9] | Gonuguntla K, Patil S, Rojulpote C, Perosevic N, Manzoor K. Amiodarone-induced myxedema coma: an endocrine emergency. Chest. 2020; 158(4): e123-e127. |
| [10] | Liu Y, Zhang H, et al. Autoimmune mechanisms in drug-induced thyroid disease. Endocr Rev. 2022; 43(1): 100–112. |
| [11] | Wang Y, Liu X, Chen J, et al. Risk factors and outcomes of amiodarone-induced thyroid dysfunction. J Clin Endocrinol Metab. 2024; 109(4): 1123–1131. |
| [12] | Kim S, Choi J, Lee M, et al. Predictors of thyroid dysfunction in patients on long-term amiodarone therapy. BMC Endocr Disord. 2024; 24: 56. |
| [13] | Rossi G, Ferrari SM, Antonelli A. Environmental and iodine-related factors in thyroid disease. Clin Endocrinol (Oxf). 2022; 97(2): 145–152. |
| [14] | Patel N, Shah M, Desai R. Cardiovascular implications of amiodarone-induced thyroid disorders. Cardiol Rev. 2023; 31(4): 210–218. |
| [15] | 9. Novak M, Kralik M, et al. Management strategies for amiodarone-induced hypothyroidism. Endocr Pract. 2023; 29(11): 1120–1128. |
APA Style
Abdikadirova, T., Trigulova, R., Nasirova, K., Jiemuratova, G. (2025). Early Diagnosis and Optimization of the Management of Amiodarone-Induced Thyroid Dysfunction in the Aral Sea Region. International Journal of Immunology, 13(4), 96-100. https://doi.org/10.11648/j.iji.20251304.13
ACS Style
Abdikadirova, T.; Trigulova, R.; Nasirova, K.; Jiemuratova, G. Early Diagnosis and Optimization of the Management of Amiodarone-Induced Thyroid Dysfunction in the Aral Sea Region. Int. J. Immunol. 2025, 13(4), 96-100. doi: 10.11648/j.iji.20251304.13
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.iji.20251304.13,
author = {Tursinay Abdikadirova and Raisa Trigulova and Khurshida Nasirova and Gulparshin Jiemuratova},
title = {Early Diagnosis and Optimization of the Management of Amiodarone-Induced Thyroid Dysfunction in the Aral Sea Region},
journal = {International Journal of Immunology},
volume = {13},
number = {4},
pages = {96-100},
doi = {10.11648/j.iji.20251304.13},
url = {https://doi.org/10.11648/j.iji.20251304.13},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.iji.20251304.13},
abstract = {Amiodarone-induced thyroid dysfunction (AITD) is a clinically significant complication, particularly in environmentally high-risk regions such as the Aral Sea area, where iodine deficiency and environmental pollution prevail. This study aimed to develop and validate an algorithm for early diagnosis and optimized management of AITD. A total of 98 patients receiving amiodarone therapy for cardiac arrhythmias were prospectively observed from 2022 to 2024. Thyroid dysfunction was classified as overt or subclinical hypothyroidism, overt or subclinical thyrotoxicosis, or euthyroid hyperthyroxinemia. Hormonal (TSH, free T4, free T3, TRAb, anti-TPO, anti-TG), biochemical, electrocardiographic, Holter, and echocardiographic parameters were assessed. Individualized therapy for hypothyroidism (L-thyroxine) and thyrotoxicosis (antithyroid drugs or glucocorticoids) was applied. The proposed algorithm enables early detection of AITD, optimization of therapy, prevention of complications, and improvement of patient outcomes in iodine-deficient regions.},
year = {2025}
}
TY - JOUR T1 - Early Diagnosis and Optimization of the Management of Amiodarone-Induced Thyroid Dysfunction in the Aral Sea Region AU - Tursinay Abdikadirova AU - Raisa Trigulova AU - Khurshida Nasirova AU - Gulparshin Jiemuratova Y1 - 2025/12/31 PY - 2025 N1 - https://doi.org/10.11648/j.iji.20251304.13 DO - 10.11648/j.iji.20251304.13 T2 - International Journal of Immunology JF - International Journal of Immunology JO - International Journal of Immunology SP - 96 EP - 100 PB - Science Publishing Group SN - 2329-1753 UR - https://doi.org/10.11648/j.iji.20251304.13 AB - Amiodarone-induced thyroid dysfunction (AITD) is a clinically significant complication, particularly in environmentally high-risk regions such as the Aral Sea area, where iodine deficiency and environmental pollution prevail. This study aimed to develop and validate an algorithm for early diagnosis and optimized management of AITD. A total of 98 patients receiving amiodarone therapy for cardiac arrhythmias were prospectively observed from 2022 to 2024. Thyroid dysfunction was classified as overt or subclinical hypothyroidism, overt or subclinical thyrotoxicosis, or euthyroid hyperthyroxinemia. Hormonal (TSH, free T4, free T3, TRAb, anti-TPO, anti-TG), biochemical, electrocardiographic, Holter, and echocardiographic parameters were assessed. Individualized therapy for hypothyroidism (L-thyroxine) and thyrotoxicosis (antithyroid drugs or glucocorticoids) was applied. The proposed algorithm enables early detection of AITD, optimization of therapy, prevention of complications, and improvement of patient outcomes in iodine-deficient regions. VL - 13 IS - 4 ER -
Department of Endocrinology, Tashkent State Medical University, Tashkent, Uzbekistan
Department of Cardiology, Republican Specialized Scientific and Practical Medical Center of Cardiology, Tashkent, Uzbekistan
Department of Endocrinology, Tashkent State Medical University, Tashkent, Uzbekistan
Department of Immunology, Nukus Branch of the Institute of Immunology and Human Genomics, Academy of Sciences of the Republic of Uzbekistan, Nukus, Uzbekistan
Information